Lifetech LAmbre: A New Promising and Novel Device in the Interventional Stroke Prevention

Schnupp, Steffen; Ajmi, Issameddine; Brachmann, Johannes; Mahnkopf, Christian

doi:10.2217/fca-2019-0040

Cited by 4 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main finding of the present report is that in patients with AF-related LAA thrombus and contraindications or lack of response to oral anticoagulation, LAA closure supported by a cerebral protection system to minimize the risk of cerebral ischemic lesions represents an efficient alternative treatment. Moreover, the double-umbrella design of the LAmbre device could constitute an advantage for these patients, allowing minimal LAA manipulation during implantation [ 15 ].…”

Section: Discussionmentioning

confidence: 99%

“…Thus, intraprocedural systemic embolization can still have serios consequences and cautious manipulation of the LAA closure device is recommended. The double-umbrella design of the LAmbre device might be a substantial advantage in preventing intraprocedural thrombus migration, allowing for partial device deployment at the LAA ostium, followed by complete delivery inside the appendage [ 15 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

“…The basis of this therapeutic approach is the ability to close the LAA, a remnant of the embryonic LA, which is considered the main source of left atrial thrombi in patients with non-valvular AF, thus limiting thrombus formation and further embolization [ 13 ]. The LAmbre device (Lifetech Scientific [Shenzhen] Co. Ltd., Shenzhen, China) demonstrated excellent implantation success rates and follow-up results, while providing a design that might provide an important advantage in patients with difficult LAA anatomy [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Percutaneous Left Atrial Appendage Closure with the LAmbre Device Protected by a Cerebral Protection System in a 76-Year-Old Man with Persistent Left Atrial Appendage Thrombus

et al. 2022

View full text Add to dashboard Cite

Patient: Male, 76-year-old Final Diagnosis: Left atrial appendage thrombus despite optimal anticoagulation Symptoms: Palpitations Medication: — Clinical Procedure: Cryoballoon-based ablation • percutaneous left atrial appendage closure • transesophageal echocardiogram Specialty: Cardiology Objective: Unusual clinical course Background: Despite use of optimal oral anticoagulation regimens, left atrial appendage (LAA) thrombus may develop and persist in patients with atrial fibrillation (AF). The therapeutic options in this population are limited. Percutaneous LAA closure (LAAC) is performed to reduce thrombus formation and the risk of thromboembolism. However, this approach is prohibited in patients with LAA thrombus. We report the case of a 76-year-old man with AF and persistent LAA thrombus who underwent percutaneous LAAC with the LAmbre device protected by the SENTINEL Cerebral Protection System (CPS). Case Report: A 76-year-old man with history of persistent AF treated with pulmonary veins and LAA isolation developed LAA thrombus resistant to different anticoagulation therapies, including apixaban and Phenprocoumon, with a target international normalized ratio (INR) of 3–3,5. Repeated follow-up transesophageal echocardiography showed a persistent LAA thrombus despite optimal INR values. Thus, we performed a percutaneous LAAC using a double-umbrella-designed appendage occluder and a CPS to minimize the risk of intraprocedural cerebral embolization. The procedure was guided by transesophageal echocardiography and fluoroscopy. No signs of systemic thromboembolism were noted, and the CPS filters showed no evidence of thrombotic material. Conclusions: This report shows that the use of a CPS during percutaneous LAAC may reduce the risk of procedural cerebral embolization and could be used as an alternative therapy for patients with contraindication or lack of effectiveness of oral anticoagulation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Percutaneous Left Atrial Appendage Closure with the LAmbre Device Protected by a Cerebral Protection System in a 76-Year-Old Man with Persistent Left Atrial Appendage Thrombus

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The implant is a nitinol-based, self-expanding device comprising a hook-embedded umbrella with a short central waist. The waist acts as an articulating, compliant connection between the cover and the umbrella, allowing the cover to self-orient the cardiac wall [ 18 ].…”

Section: Methodsmentioning

confidence: 99%

Overcoming barriers for left atrial appendage thrombus: a systematic review of left atrial appendage closure

Zhang,

Zhou,

Lin

et al. 2024

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Approximately 90% of intracardial thrombi originate from the left atrial appendage in non-valvular atrial fibrillation patients. Even with anticoagulant therapy, left atrial appendage thrombus (LAAT) still occurs in 8% of patients. While left atrial appendage closure (LAAC) could be a promising alternative, the current consensus considers LAAT a contraindication to LAAC. However, the feasibility and safety of LAAC in patients with LAAT have yet to be determined. Methods This systematic review synthesizes published data to explore the feasibility and safety of LAAC for patients with LAAT. Results This study included a total of 136 patients with LAATs who underwent successful LAAC. The Amulet Amplatzer device was the most frequently utilized device (48.5%). Among these patients, 77 (56.6%) had absolute contraindications to anticoagulation therapy. Cerebral protection devices were utilized by 47 patients (34.6%). Transesophageal echocardiography (TEE) is the primary imaging technique used during the procedure. Warfarin and novel oral anticoagulants were the main anticoagulant medications used prior to the procedure, while dual antiplatelet therapy was primarily used post-procedure. During a mean follow-up period of 13.2 ± 11.5 months, there was 1 case of fatality, 1 case of stroke, 3 major bleeding events, 3 instances of device-related thrombus, and 8 cases of peri-device leakage. Conclusions This review highlights the preliminary effectiveness and safety of the LAAC procedure in patients with persistent LAAT. Future large-scale RCTs with varied LAAT characteristics and LAAC device types are essential for evidence-based decision-making in clinical practice.

show abstract

Impact of left atrial appendage orifice diameter on the safety and efficacy of left atrial appendage closure using the LAmbre device

Zhuo,

Wang,

et al. 2024

Journal of the Formosan Medical Association

View full text Add to dashboard Cite

Lifetech LAmbre: A New Promising and Novel Device in the Interventional Stroke Prevention

Cited by 4 publications

References 18 publications

Percutaneous Left Atrial Appendage Closure with the LAmbre Device Protected by a Cerebral Protection System in a 76-Year-Old Man with Persistent Left Atrial Appendage Thrombus

Percutaneous Left Atrial Appendage Closure with the LAmbre Device Protected by a Cerebral Protection System in a 76-Year-Old Man with Persistent Left Atrial Appendage Thrombus

Overcoming barriers for left atrial appendage thrombus: a systematic review of left atrial appendage closure

Impact of left atrial appendage orifice diameter on the safety and efficacy of left atrial appendage closure using the LAmbre device

Contact Info

Product

Resources

About